Xilio Therapeutics Statistics
Total Valuation
XLO has a market cap or net worth of $37.85 million. The enterprise value is -$51.23 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XLO has 51.77 million shares outstanding. The number of shares has increased by 136.13% in one year.
| Current Share Class | 51.77M |
| Shares Outstanding | 51.77M |
| Shares Change (YoY) | +136.13% |
| Shares Change (QoQ) | +15.50% |
| Owned by Insiders (%) | 14.07% |
| Owned by Institutions (%) | 18.43% |
| Float | 21.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.14 |
| Forward PS | 1.97 |
| PB Ratio | 5.10 |
| P/TBV Ratio | 3.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -569.57 |
Financial Efficiency
Return on equity (ROE) is -297.84% and return on invested capital (ROIC) is -156.69%.
| Return on Equity (ROE) | -297.84% |
| Return on Assets (ROA) | -38.21% |
| Return on Invested Capital (ROIC) | -156.69% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | $144,906 |
| Profits Per Employee | -$848,484 |
| Employee Count | 64 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.05% in the last 52 weeks. The beta is -0.23, so XLO's price volatility has been lower than the market average.
| Beta (5Y) | -0.23 |
| 52-Week Price Change | -38.05% |
| 50-Day Moving Average | 0.77 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 47.61 |
| Average Volume (20 Days) | 259,885 |
Short Selling Information
The latest short interest is 351,157, so 0.68% of the outstanding shares have been sold short.
| Short Interest | 351,157 |
| Short Previous Month | 562,279 |
| Short % of Shares Out | 0.68% |
| Short % of Float | 1.60% |
| Short Ratio (days to cover) | 2.42 |
Income Statement
In the last 12 months, XLO had revenue of $9.27 million and -$54.30 million in losses. Loss per share was -$0.83.
| Revenue | 9.27M |
| Gross Profit | 11.41M |
| Operating Income | -56.96M |
| Pretax Income | -65.53M |
| Net Income | -54.30M |
| EBITDA | -55.35M |
| EBIT | -56.96M |
| Loss Per Share | -$0.83 |
Full Income StatementBalance Sheet
The company has $89.07 million in cash and n/a in debt, giving a net cash position of $89.07 million or $1.72 per share.
| Cash & Cash Equivalents | 89.07M |
| Total Debt | n/a |
| Net Cash | 89.07M |
| Net Cash Per Share | $1.72 |
| Equity (Book Value) | 10.70M |
| Book Value Per Share | 0.14 |
| Working Capital | 89.07M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 123.01% |
| Operating Margin | -614.16% |
| Pretax Margin | -585.54% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |